MENU
PDEX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

PDEX stock forecast, quote, news & analysis

Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries... Show more

PDEX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
A.I.Advisor
a Summary for PDEX with price predictions
Jul 31, 2026

PDEX sees its Stochastic Oscillator ascending out of oversold territory

On July 28, 2026, the Stochastic Oscillator for PDEX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on PDEX as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PDEX just turned positive on July 31, 2026. Looking at past instances where PDEX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PDEX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

PDEX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

PDEX moved below its 50-day moving average on July 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PDEX crossed bearishly below the 50-day moving average on July 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDEX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PDEX entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PDEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.137) is normal, around the industry mean (5.137). P/E Ratio (16.130) is within average values for comparable stocks, (202.232). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.455). Dividend Yield (0.000) settles around the average of (0.021) among similar stocks. P/S Ratio (2.600) is also within normal values, averaging (84.005).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.1B. The market cap for tickers in the group ranges from 126 to 124.82B. ISRG holds the highest valuation in this group at 124.82B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 5%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was -2%. SMTI experienced the highest price growth at 32%, while FEMY experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 62
Price Growth Rating: 53
SMR Rating: 84
Profit Risk Rating: 96
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
PDEX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a producer of powered solutions

Industry PharmaceuticalsOther

Profile
Details
Industry
Medical Or Nursing Services
Address
2361 McGaw Avenue
Phone
+1 949 769-3200
Employees
181
Web
https://www.pro-dex.com
PDEX sees its Stochastic Oscillator ascending out of oversold territory